Physician profile
Michael E Rubio
NPI 1568967727
$9,164.48
in general payments reported to CMS, 2019-2025
14 companies · $813 in 2025
The $813 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.46 · 2023: $2,777 · 2024: $5,498 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,652 · Food and Beverage: $2,238 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,651.50 |
| Food and Beverage | $2,237.53 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,792.73 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $2,904.94 | 2022-2025 | |
| Leo Pharma INC. | $1,357.14 | 2024-2025 | Adbry |
| Janssen Biotech, INC. | $400.85 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $280.96 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $129.77 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $88.30 | 2023-2024 | Dupixent |
| Abbvie INC. | $52.10 | 2022-2025 | |
| Almirall LLC | $34.84 | 2025 | Klisyri |
| Ucb, INC. | $34.38 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $33.87 | 2025 | |
| Biofrontera INC. | $22.15 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $18.16 | 2023 | Otezla |
| Mayne Pharma Commercial LLC | $14.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rubio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.